Milestone Scient SEC Filings

Milestone Scientific Inc. reported Q3 2025 results, highlighting modest sales and continued losses alongside a going concern warning. Product sales, net were $2.36 million versus $2.51 million a year ago. Gross profit was $1.64 million, and the operating loss was $1.13 million, compared with a $1.47 million loss last year. Net loss was $1.15 million, or $0.01 per share.

Dental drove nearly all revenue ($2.32 million), while Medical contributed $41 thousand. Cash and cash equivalents were $1.35 million, with working capital of about $3.1 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern and plans to seek additional financing.

For the nine months, operating cash use was $2.69 million. The company issued $800,000 of unsecured, related‑party convertible notes in April 2025. E‑commerce accounted for 43% of Q3 net product sales. Shares outstanding were 78,628,913 as of November 12, 2025.

Milestone Scientific Inc. (MLSS) filed its definitive proxy for the virtual annual meeting on December 18, 2025. Stockholders will vote on three proposals: elect six directors; amend the Restated Certificate of Incorporation to increase authorized common stock from 100,000,000 to 125,000,000; and ratify CBIZ CPAs P.C. as independent auditors for the year ending December 31, 2025.

For the amendment to increase authorized shares, approval requires a majority of the Company’s outstanding common stock. As of the record date, November 4, 2025, there were 78,628,913 shares outstanding, each entitled to one vote. The filing notes the Board’s view that additional authorized shares would provide flexibility for financings, equity awards and strategic transactions, while also acknowledging potential dilution from future issuances.

The Board recommends voting “FOR” all proposals. The proxy also details governance practices, director independence, executive and director compensation highlights, and related‑party items, including an aggregate $800,000 convertible notes financing with three directors dated April 9, 2025, and the CEO’s signing grant of options for 2,000,000 shares at an exercise price of $0.50.

Milestone Scientific (MLSS) reported insider activity on Form 4. A director disclosed open‑market sales of common stock on three dates: 14,427 shares at $0.4497 on 10/22/2025, 80,000 shares at $0.4302 on 10/23/2025, and 100,000 shares at $0.4398 on 10/24/2025.

Following these transactions, the reported beneficial ownership changed as follows: 9,076,765 shares after 10/22, 8,996,765 shares after 10/23, and 8,896,765 shares after 10/24, all listed as Direct ownership. The form is signed by /S/ Dr. Pedro Palau, Liquidator.

Milestone Scientific (MLSS) reported insider stock sales. On 10/20/2025, the filer sold 24,034 shares of common stock at $0.4527, leaving 9,131,192 shares beneficially owned directly. On 10/21/2025, the filer sold an additional 40,000 shares at $0.4398, with 9,091,192 shares directly owned afterward.

The form was filed by one reporting person. The signature block shows /S/ Dr. Pedro Palau, Liquidator.

Milestone Scientific (MLSS) disclosed insider stock sales on a Form 4. The reporting person sold common stock in three transactions: 10,158 shares on 10/10/2025 at $0.5501, 10,000 shares on 10/13/2025 at $0.55, and 30,000 shares on 10/14/2025 at $0.5395. Following these transactions, the reporting person beneficially owned 9,155,226 shares, held directly.

Milestone Scientific Inc. reported it received a NYSE American notice that it is not in compliance with continued listing standards under Sections 1003(a)(ii) and (iii). The company must submit a plan of compliance by November 7, 2025. If the plan is accepted, the listing can continue with periodic reviews.

The Exchange may initiate delisting procedures if the plan is not accepted, if progress is insufficient, or if the company fails to regain compliance by April 8, 2027. Management is pursuing options to address the deficiency and intends to submit a plan by the deadline.

BP4 S.r.l., listed as a Director and 10% Owner, reported insider sales of common stock in MILESTONE SCIENTIFIC INC. (MLSS).

The filing shows two sales: 10,000 shares sold on 10/07/2025 at $0.45 and 30,000 shares sold on 10/08/2025 at $0.465, a total of 40,000 shares. Following the transactions, the reporting person reported beneficial ownership of 9,195,384 shares.

The form is signed by /s/ Dr. Pedro Palau, Liquidator on 10/09/2025. The transactions are reported as direct ownership changes and involve common stock only.

BP4 S.r.l., a director-level reporting person, reported the sale of a total of 19,210 shares of MILESTONE SCIENTIFIC INC. (MLSS) on 10/03/2025 at prices of $0.4491 and $0.45. After these disposals the reporting person beneficially owned 9,235,384 shares. No derivative transactions are reported and the Form 4 is signed by the liquidator on 10/08/2025.

BP4 S.r.l., listed as a director of Milestone Scientific Inc. (MLSS), reported a sale of 10,000 shares of the issuer's common stock on 09/11/2025 at a price of $0.594 per share. After the transaction the filing indicates beneficial ownership of 9,256,972 shares, held indirectly. The Form 4 was signed by Dr. Pedro Palau, Liquidator and filed on 09/15/2025. The filing shows a single non-derivative disposition and does not disclose any derivative transactions or a Rule 10b5-1 plan.